Filed Nov 24, 2025Period of report Nov 20, 20250001615219-25-000193
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseNov 20, 2025
Common StockF1
5,000
$0.7481
$3.74K
5,015
Indirect
Rosenblum Mark JExec VP Finance, CFO
4
Filed Nov 20, 2025Period of report Nov 20, 20250001615219-25-000177
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseNov 20, 2025
Common StockF1F2
20,000
$0.80
$16.00K
20,177
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.
By Arnold C. Hanish Trust
Filing footnotes · 1
F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7437 to $0.75, inclusive. The reporting person undertakes to provide to Salarius Pharmaceuticals, Inc., any security holder of Salarius Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.